1,2,3-Triazole-Containing Compounds as Anti–Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure–Activity Relationship

Ting Liang†, Xiangyang Sun††, Wenhong Li3, Guihua Hou1 and Feng Gao1*

1 Key Laboratory for Experimental Teratology of the Ministry of Education and Biomedical Isotope Research Center, School of Basic Medical Sciences, Cheebo College of Medicine, Shandong University, Jinan, China, 2 Department of Interventional Radiology, Qilu Hospital of Shandong University, Jinan, China, 3 Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

Lung cancer is the most common malignancy and leads to around one-quarter of all cancer deaths. Great advances have been achieved in the treatment of lung cancer with novel anticancer agents and improved technology. However, morbidity and mortality rates remain extremely high, calling for an urgent need to develop novel anti–lung cancer agents. 1,2,3-Triazole could be readily interact with diverse enzymes and receptors in organisms through weak interaction. 1,2,3-Triazole can not only be acted as a linker to tether different pharmacophores but also serve as a pharmacophore. This review aims to summarize the recent advances in 1,2,3-triazole–containing compounds with anti–lung cancer potential, and their structure–activity relationship (SAR) together with mechanisms of action is also discussed to pave the way for the further rational development of novel anti–lung cancer candidates.

Keywords: hybrid molecules, lung cancer, anticancer, structure–activity relationship, triazole

INTRODUCTION

Lung cancer has high morbidity and represents the leading cause of cancer-related deaths (around 20% of all mortalities in cancer) (Nasim et al., 2019; Willis et al., 2019; Bade and Dela Cruz, 2020; Majem et al., 2020; Salehi et al., 2020; Zhang et al., 2020). With the development of novel anticancer agents and improvement of technology, lung cancer treatment has achieved great progress in recent decades, but the morbidity and mortality rates remain high and the overall 5-year survival rate is only around 15% (Gray et al., 2019; Coakley and Popat, 2020).

1,2,3-Triazole moiety (Figure 1), a major pharmacophore system among nitrogen-containing heterocycles, can be obtained readily using “click” chemistry with copper- or ruthenium-catalyzed azide-alkyne cycloaddition reactions and it can also act as a linker to tether different pharmacophores. Moreover, 1,2,3-triazole could form diverse non-covalent interactions, such as hydrogen bonds, van der Waals forces, and dipole–dipole bonds with various enzymes, proteins, and receptors (Bonandi et al., 2017; Bozorov et al., 2019). Hence, 1,2,3-triazole derivatives exhibit a variety of promising biological properties, including antibacterial (Zhang, 2019; Xu, 2020), antimalarial (Chu et al., 2019; Feng et al., 2020), antitubercular (Zhang et al., 2017; Yan et al., 2020), antiviral (Rani et al., 2020; Feng et al., 2021), and anticanic (Lal and Yadav, 2018; Slavova et al., 2020) activities. For example, 1,2,3-
Triazoles could exert the anticancer potential by inducing the cell cycle arrest and apoptosis of cancer cells. The 1,2,3-triazole–containing agent carboxyamidotriazole (CAI) could synergise with sorafenib to combat NSCLC by inhibiting NANOG and aggravating apoptosis (Ferreira et al., 2013; Chen et al., 2017). These studies suggest that 1,2,3-triazole derivatives are useful scaffolds for development of novel anti–lung cancer agents with low toxicity and high efficacy.

In recent years, a variety of 1,2,3-triazole–containing compounds are designed, synthesized, and evaluated for their anti–lung cancer activity, and some of them have the potential to act on dual-/multi-targets simultaneously (Jain and Piplani, 2019; Xu et al., 2019; Farrer and Griffith, 2020; Sahu et al., 2020). This review summarizes the current developments, mechanisms of action, and structure–activity relationships (SARs) of 1,2,3-triazole–containing compounds with anti–lung cancer potential to pave the way for further rational development.

1,2,3-Triazole–containing chromene derivatives 1 (Figure 2) possess broad-spectrum activity against six human cancer cell lines, and an antiproliferative SAR study against the A549 lung cancer cell line (IC$_{50}$: 1.02–74.28 μm, MTT assay) revealed that the fluoro atom on the phenyl ring contributes to the activity. However, 1,2,3-triazole is not crucial for the activity and replacement of 1,2,3-triazole by 1,2,4-triazole is also tolerated (Luan et al., 2020). In addition, the phenyl group at the C-2 position of the chromene moiety has great influence on the activity, as evidenced by the decreased activity of compounds 2 (IC$_{50}$: 32.4–596.6 μm, MTT assay) against A549 cells (Wu et al., 2019). Among them, compounds 1a,b (IC$_{50}$: 27.89 μm), the most active against A549 cells, are less potent than the reference Chrysin (IC$_{50}$: 8.80 μm).

1,2,3-Triazole–containing chromene derivatives 3 (IC$_{50}$: 0.28–6.30 μm, MTT assay) exhibit excellent activity against...
A549, taxol-resistant A549 (A549/taxol), and cisplatin-resistant A549 (A549/cisplatin) cancer cell lines, and an SAR study proved that the morpholino group at the R position could enhance the activity (Li et al., 2017). In particular, compound 3a (DDO-6318, IC_{50}: 0.31–0.42 μm) is highly potent against A549, A549/taxol and A549/cisplatin lung cancer cell lines, and the resistance index (RI: IC_{resistant cells}/IC_{sensitive cells}) is approximately 1, demonstrating its potential for the treatment of drug-sensitive and drug-resistant lung cancers. The activity of DDO-6318 is at the same level as those of DDO-6106 (IC_{50}: 0.46 μm) and gambogenic acid (IC_{50}: 0.29 μm) against A549/taxol cells but is around eight times superior to those of DDO-6106 (IC_{50}: 0.46 μm) and gambogenic acid (IC_{50}: 0.29 μm) against A549 and A549/cisplatin cells. In the mouse model xenografted with A549, DDO-6318 (71.32% inhibition in tumor growth at 20 mg/kg, twice daily doses/BID, and intravenous administration) displays significant inhibitory effect on the growth of inoculated A549 in mice without causing vascular irritation or weight loss, and its activity is higher than those of DDO-6101 (34.56% inhibition at 20 mg/kg) and 5-fluorouracil (64.71% inhibition at 20 mg/kg). Similar results were also observed when oral administraion of DDO-6318 (66.43% inhibition at 50 mg/kg daily oral dose for DDO-6318 and 21.43% inhibition for DDO-6101 at the same dose). Thus, DDO-6318 can be considered as a new and orally active natural product-like anti-lung cancer candidate for further clinical studies.

Some 1,2,3-triazole-containing coumarin derivatives 4 (IC_{50}: 0.8–27.08 μm, MTT assay) are active against various cancer cell lines, and an antiproliferative SAR study against A549 cells illustrates that the methyl group at the R1 position could result in the improved activity (Liu et al., 2017; Goud et al., 2019). Among them, compounds 4a,b (IC_{50}: 2.97 and 4.78 μm) are more potent than cisplatin (IC_{50}: 24.15 μm) against A549 cells. Moreover, compound 4a (IC_{50}: 49.07 μm) shows low cytotoxicity toward mouse embryonic fibroblast cells NIH/3T3, and the selective index (SI: IC_{50(NIH-3T3)}/IC_{50(A549)}) is 16.5. A mechanistic study elucidated that compound 4a could induce sub-G1 phase arrest, increase apoptosis, decrease the mitochondrial membrane potential, and promote reactive oxygen species (ROS) production. 1,2,3-Triazole-containing coumarin derivatives 5 (IC_{50}: 8.73–100 μm, MTT assay) show weak to moderate activity against a panel of cancer cell lines, including A549 cells, and a strong correlation exists between lipophilicity profile and antiproliferative activity (Kraljevic et al., 2016). Compound 5a (IC_{50}: 8.87 μm) displays the highest inhibitory activity against A549 cells, but it is toxic against normal fibroblasts W138 (IC_{50}: 13.96 μm).

Generally, incorporation of the third fragment, such as β-lactam (Dhwaw et al., 2020) and uracil (Sanduja et al., 2020), is detrimental to the antiproliferative activity against lung cancer cells, but some 1,2,3-triazole-tethered coumarin-isatin hybrids, such as compound 6 (IC_{50}: 18.67 μm, SRB assay), show certain activity against A549 cells (Diao et al., 2019; Xu et al., 2019). Hence, these compounds still need further modification.

1,2,3-TRIAZOLE-CONTAINING CHALCONE DERIVATIVES

Chalcones are scaffolds that appear as an important structural component in various natural products and possess some useful biological properties. Chalcones are potential inhibitors of aromatase, P-glycoprotein (P-gp), histone deacetylase (HDAC), matrix metalloproteinase (MMP), NF-κB, tubulin, vascular endothelial growth factor, and vascular endothelial growth factor receptor 2 (VEGFR-2) kinase; thus, chalcones are endowed with broad-spectrum antiproliferative activity against drug-susceptible and drug-resistant cancers, even MDR cancers (Karthikeyan et al., 2015; Gao et al., 2020). Accordingly, 1,2,3-triazole-containing chalcone derivatives are useful prototypes for the discovery of novel anticancer candidates.

1,2,3-Triazole-containing chalcone derivatives 7 (Figure 3, IC_{50}: 8.67–11.62 μm, MTT assay) show potential activity against A549 cells. An SAR study illustrated that the bromo group is essential for the activity, and replacement by heterocycles results in loss of activity (Vanaparthi et al., 2020). Among them, compounds 7a,c (IC_{50}: 8.67 and 9.74 μm) with single digital micromolar inhibitory activity are comparable to doxorubicin (IC_{50}: 3.24 μm). Compounds 8 (IC_{50}: 9–60 μm, MTT assay) are active against A549 cells, and a mechanistic study revealed that these compounds could exert antiproliferative activity by inducing apoptosis and G2/S arrest as well as triggering mitochondrial potential loss (Yadav et al., 2017). An SAR study demonstrated that introducing a methoxy group into the phenyl ring could not increase the activity apparently, and the activity of compounds 9 (GI_{50}: 4.7–11.9 μm, SRB assay) is considerably inferior to that of combretastatin-A4 (GI_{50}: 0.08 μm) against A549 cells (Hussaini et al., 2016). Further study proved that the benzyl group at the N-1 position of the 1,2,3-triazole moiety is not crucial for the activity, and replacement by the phenyl ring is also permitted, as evidenced by that compounds 10a,b (IC_{50}: 62.51 and 75.41 μm, MTT assay) show comparable activity to doxorubicin (IC_{50}: 39.86 μm) against A549 cells (Raghavender et al., 2020). The 1,2,3-triazole–containing chalcone compounds 11a-c (IC_{50}: 35.81–50.82 μm, MTT assay) are more potent than doxorubicin (IC_{50}: 69.33 μm) against A549 cells, demonstrating their potential to fight against lung cancer (Chinthala et al., 2015).

The antiproliferative SAR of 1,2,3-triazole–tethered chalcone-matrine hybrids 12a–c (IC_{50}: 5.01–12.72 μm, MTT assay) against A549 cells reveals that the electron-withdrawing group at the R position could boost up the activity, and the representative compound 12a (IC_{50}: 5.01–7.31 μm) not only exhibits the highest activity against the four tested cancer cell lines but also displays low cytotoxicity (IC_{50}: 39.21 μm) toward normal NIH/3T3 cells (Zhao et al., 2015). A mechanistic study reveals that compound 12a could induce the apoptosis of A549 cells concentration-dependently in the A549-xenografted nude mouse model, and it also (10 mg/kg, tail vein injection) shows 85.4% tumor growth inhibition (TGI) after treatment for 16 days without causing obvious toxicities. Accordingly, compound
12a could be considered as a promising candidate for the chemotherapy of lung cancer.

1,2,3-TRIAZOLE–CONTAINING INDOLE DERIVATIVES

Indoles, which could inhibit various enzymes and receptors, such as HDAC, proviral insertion site in moloney murine leukemia virus (Pim), and tubulin in cancer cells, are scaffolds to avail for developing novel anticancer agents (Guo and Diao, 2020; Xu and Xu, 2020). Thus, combination of 1,2,3-triazole with indole represents a promising strategy to develop novel anticancer candidates that are effective against drug-sensitive and drug-resistant cancers.

An antiproliferative SAR study of 1,2,3-triazole–containing etodolac derivatives 13 (Figure 4, IC₅₀: 3.29–10.71 μM, MTT assay) against A549 cells revealed that the phenyl ring is crucial for the activity, and replacement by the naphthyl group results in loss of activity (Kummari et al., 2017). Introduction of substituents into the phenyl ring is generally detrimental to the activity, whereas methyl at the para position could enhance the activity slightly. The most active compounds 13a,b (IC₅₀: 3.65 and 3.29 μM) display comparable activity to doxorubicin (IC₅₀: 3.30 μM). Thus, these compounds can serve as promising lead candidates for further investigations.
Triazole–containing indole derivatives 14 (IC$_{50}$: 9.07–47.11 μm, MTT assay) and 15 (IC$_{50}$: 15.25–38.68 μm, MTT assay) show considerable activity against A549 cells, and the most potent compound 14a (IC$_{50}$: 9.07 μm) is not inferior to doxorubicin (IC$_{50}$: 4.39 μm) (Srinivas et al., 2020; Suryapeta et al., 2020).

The majority of spirooxindole-derived morpholine-fused 1,2,3-triazoles 16 (IC$_{50}$: 1.87–23.44 μm, MTT assay) are active against A549 cells, and an SAR study implied that the para bromobenzyl group is more favorable than the alkyl group at the N-1 position of oxindole moiety (Senwar et al., 2015). In particular, the activity of compound 16a (IC$_{50}$: 1.87 μm) is comparable to that of doxorubicin (IC$_{50}$: 1.98 μm) but 3.8-fold superior to that of 5-fluorouracil (IC$_{50}$: 7.24 μm). Further investigations demonstrated that compound 16a could arrest the A549 cells at the G2/M phase of the cell cycle and induce apoptosis in A549 cells through collapse of the mitochondrial membrane potential as well as elevation of intracellular ROS levels. Overall, compound 16a has the potential to act as a lead compound for the development of novel anticancer agents against lung adenocarcinoma A549 cancer cells.

An antiproliferative SAR study of 1,2,3-triazole–containing isatin compounds 17 (IC$_{50}$: 0.99–27.33 μm, MTT assay) against NCI-H23 lung cancer cells disclosed that substituents at the C-3 and C-5 positions have great influence on the activity (Lan et al., 2020). Introduction of oxime to the C-3 position could increase the activity, and the relative contribution order is methoxime > oxime > ketone. Electron-donating methoxy and halogen atoms at the C-5 position are preferred, whereas movement to the C-7 position causes great loss of activity. In particular, the most active compound 17a (IC$_{50}$: 0.65 μm, MTT assay) is around 2 and 13 times superior to doxorubicin (IC$_{50}$: 1.12 μm) and 5-fluorouracil (IC$_{50}$: 8.84 μm), respectively. Some other 1,2,3-triazole–containing isatin compounds also hold certain activity against A549 cells, and the representative compounds 18a,b (IC$_{50}$: 14.7 and 9.6 μm, MTT assay) demonstrate the highest activity (Sharma et al., 2015; Nagarsenkar et al., 2016; Fan et al., 2018; Xu et al., 2018). Mechanistic studies indicate that hybrid 18a could induce cell apoptosis, cause cell cycle arrest at the G2/M phase, and lead to collapse of the mitochondrial membrane potential (Nagarsenkar et al., 2016).

### 1,2,3-Triazole–Containing Podophyllotoxin/Epipodophyllotoxin Derivatives

Podophyllotoxins show antiproliferative activity by inhibiting tubulin polymerization, and epipodophyllotoxins are inhibitors of topoisomerase II (Sathish et al., 2018; Xiao et al., 2020). Some podophyllotoxin-/epipodophyllotoxin-based agents, such as...
etoposide and teniposide, have already been approved for cancer therapy, revealing that podophyllotoxin/epipodophyllotoxin derivatives are promising as novel anticancer agents (Kamal et al., 2015; Routh and Nandagopal, 2017).

1,2,3-Triazole–containing podophyllotoxin derivatives 19 (Figure 5, IC₅₀: 21.1–118.8 nM, MTT assay) are highly potent against A549 cells, and compounds 19a-c (IC₅₀: 21.1–29.4 nM) are comparable to podophyllotoxin (IC₅₀: 27.1 nM) (Hou et al., 2019). Mechanistic investigations show that hybrid 19a could exert antiproliferative activity through acting on microtubules, causing cell cycle arrest at the G2/M phase, and inducing apoptosis cancer cells.

1,2,3-Triazole–containing epipodophyllotoxin derivatives 20 (IC₅₀: 0.97–34.46 μM, MTT assay) exhibit considerable activity against A549 cells, and an SAR study implies that introduction of a carbon spacer between 1,2,3-triazole and phenyl ring reduces the activity (Reddy et al., 2018). Compounds 20a-e (IC₅₀: 0.97–1.96 μM) possess higher activity than the references podophyllotoxin (IC₅₀: 4.60 μM) and etoposide (IC₅₀: 1.97 μM), and the cytotoxicity (IC₅₀: 53.86–89.04 μM) toward NIH/3T3 cells is much lower. A mechanistic study demonstrates that these hybrids could inhibit topoisomerase II, arrest G2/M phase of cell cycle, and induce apoptosis.

1,2,3-Triazole–tethered podophyllotoxin-coumarin hybrids 21 (IC₅₀: 8.6–34.8 μM, MTT assay) show higher antiproliferative activity than their analogues 22 (IC₅₀: 19.6–>100 μM) against A549 cells, revealing that the amino linker to couple 1,2,3-triazole with coumarin moieties is more favorable than ether linker (Hao et al., 2019). In addition, substituents into the C-6 position of the coumarin moiety and the electron-withdrawing group are beneficial for the activity. In particular, hybrids 21a,b (IC₅₀: 8.6 and 17.5 μM) are found much more potent than the reference etoposide (IC₅₀: 25.6 μM) against A549 cells, and hybrid 21b could disrupt microtubules and induce cell cycle arrest at the G1 phase by regulating P21 and cyclin D1.

1,2,3-Triazole–tethered epipodophyllotoxin-galactose hybrid 23a possesses potent broad-spectrum antiproliferative activity, and the activity against A549 cells (IC₅₀: 4.07 μM, MTT assay) is 2-fold higher than that of cisplatin (IC₅₀: 9.24 μM) and etoposide (IC₅₀: 11.92 μM) (Zi et al., 2015). An SAR study reveals that butyrylation of the galactose moiety generally benefits for the activity, as evidenced by that hybrid 23b (IC₅₀: 1.52 μM) is six times superior to cisplatin (IC₅₀: 9.24 μM) and etoposide (IC₅₀: 11.92 μM) against A549 cells (Zi et al., 2015).

The majority of 1,2,3-triazole–tethered epipodophyllotoxin-bis-glucose hybrids (IC₅₀: > 40 μM, MTT assay) are devoid of activity against A549 cells, but hybrid 24 (IC₅₀: 3.84 μM) demonstrates higher activity than the references cisplatin (IC₅₀: 6.15 μM) and etoposide (IC₅₀: 11.92 μM) (Zi et al., 2017). Similar results are also observed for bis-1,2,3-triazole–tethered bis-epipodophyllotoxin-glucose hybrids (IC₅₀: > 40 μM, MTT assay). Only hybrid 25 (IC₅₀: 0.89 μM) displays...
excellent inhibitory activity against A549 cells, and the activity is 6.9- and 13.3-folds superior to those of cisplatin (IC50: 6.15 μM) and etoposide (IC50: 11.92 μM) (Zi et al., 2018). This hybrid (CC50: 15.38 μM) also shows relatively low cytotoxicity against normal BEAS-2B cells, and the SI is 17.2. Accordingly, hybrid 25 could serve as a lead compound for further investigations.

1,2,3-TRIAZOLE–CONTAINING QUINOLINE/QUINOLONE DERIVATIVES

Quinoline and quinolone derivatives are potential inhibitors of hepatocyte growth factor receptor, proto-oncogene receptor tyrosine kinase/KIT, platelet-derived growth factor receptor-β/PDGFR-β and VEGFR2, and some quinoline/quinolone-based agents, such as anlotinib and lenvatinib, have already been approved for lung cancer therapy (Jain et al., 2019; Li and Zhu, 2021). Hence, combination of 1,2,3-triazole with quinoline/quinolone may provide valuable therapeutic drug candidates against lung cancer.

The majority of 1,2,3-triazole–containing quinoline derivatives (IC50: 7.6–164 μM, SAR assay) are active against H460 and HCC827 human lung cancer cell lines, and compound 26 (EAD1, Figure 6, IC50: 11 and 7.6 μM) is more potent than chloroquinoline (IC50: 52 and 76 μM) (Nordström et al., 2015). A mechanistic study indicates that compound 26 exerts antiproliferative activity by inhibiting autophagy and inducing apoptosis. Compound 27 (GI50: 0.189–2.17 μM, SRB assay) demonstrates promising activity against a series of cancer cell lines, including eight NSCLC (GI50: 0.25–1.91 μM), and a mechanistic study reveals that this hybrid could induce apoptosis (Kandi et al., 2015). Compounds 28 (IC50: 0.07–3.50 μM, MTT assay) display potential activity against A549 cells, and an SAR study elucidates that the piperidinyl group at the R1 position enhances the activity (Liu et al., 2016). Among them, compounds 28a–c (IC50: 0.07–0.14 μM) are not inferior to foretinib (IC50: 0.11 μM). In particular, the most active compound 28a with an IC50 value of 2.27 nM against c-Met is identified as a multitargeted receptor tyrosine kinase inhibitor. Thus, this compound is worthy of further investigation. Some 1,2,3-triazole–containing 2-chloroquinoline derivatives, such as compound 29 (IC50: 9.8 μM against A549 cells, MTT assay; 9.7 μM for doxorubicin), also display certain antiproliferative activity against lung cancer cells, but most of them are less potent than the references (Praveena et al., 2016; Dasari et al., 2019). Further modifications imply that incorporation of azole between 1,2,3-triazole and quinoline moieties is also allowed, and 1,2,3-triazole–tethered 1,3,4-oxadiazole-quinoline compound 30 (IC50: 5.6 μM, MTT assay) is comparable to doxorubicin (IC50: 1.83 μM) against A549 cells (Rachakonda et al., 2017; Shamsi et al., 2019).

The antiproliferative activity of 1,2,3-triazole–containing quine derivatives 31a,b (IC50: 3.3 and 4.7 μM, MTT assay) is comparable to that of cisplatin (IC50: 3.5 μM) against A549 cells (Boratynski et al., 2018), while compound 32 (IC50: 2.34 and 2.13 μM, MTT assay) shows promising activity against drug-sensitive NCI-H460 and MDR NCI-H460/R; probably due to that this compound could increase ROS production and induce mitochondrial damage in MDR cancer cells, demonstrating its potential against MDR lung carcinoma (Podolski-Renic et al., 2017). Aside from the 1,2,3-triazole–containing quinoline derivatives mentioned above, some other derivatives are also endowed with certain activity against lung cancer cells (Theeramunkong et al., 2016; Zeng et al., 2017; Qiao et al., 2019; Rono et al., 2019). 1,2,3-Triazole–containing benzofuroquinoline derivatives 33a,b (IC50: 0.53 and 0.26 μM, MTT assay) exhibit excellent activity against A549 cells and low cytotoxicity (IC50: 25.24 and 16.05 μM) toward mouse mesangial cells (Zeng et al., 2017). A mechanistic study reveals that compound 33b could exert antiproliferative activity by inducing G0/G1 phase arrest and down-regulating c-myc gene transcription.

1,2,3-Triazole–tethered ciprofloxacin/gatifloxicin/moxifloxacin-isatin hybrids are also active against A549 cells, and hybrid 34 (IC50: 44.2 μM, CCK-8 assay) is more potent than vorinostat (IC50: 76.3 μM), revealing that these types of hybrids could be taken for further investigations (Chen et al., 2019; Jiang and Zhang, 2019; Yang et al., 2020).

1,2,3-TRIAZOLE–CONTAINING PYRIDINE DERIVATIVES

Pyridines are potential inhibitors of CDK, EGFR, PI3K, and RGFR, and some pyridine-based agents, such as masitinib, have already been approved in clinical practice or under clinical trials for the treatment of cancers (Goel et al., 2016; Prachayasittikul et al., 2017). Thus, combination of 1,2,3-triazole with pyridine may provide opportunities for the development of novel anticancer agents.

An antiproliferative SAR of 1,2,3-triazole–containing pyridine derivatives 35 (Figure 7, IC50: 1.023–23.61 μM, MTT assay) against A549 cells indicates that the methoxy group on the 2-arylpyridine moiety (R1 position) and the 3-phenoxy group on the benzyl group are favorable for the activity (Kamal et al., 2015; Prasad et al., 2019). The most active compounds 35a-c (IC50: 1.023–1.148 μM) exhibit higher activity than the reference E7010 (IC50: 1.622 μM), and mechanistic studies reveal that these compounds could inhibit the microtubule assembly, arrest the cell cycle at the G2/M phase, and induce cell death by apoptosis. BD7 (36, IC50: 0.07–0.49 μM, MTT assay) shows potent antiproliferative activity against various cancer cell lines, and its activity is identical to that of sorafenib (IC50: 0.08–0.30 μM) (Pan et al., 2019). Biological results indicate that BD7 displays simultaneous inhibition of VEGFR-2, Tie-2, and EphB4. Thus, this compound could be considered as a promising template for further optimization of 1,2,3-triazole–incorporated derivatives as VEGFR-2/Tie-2/EphB4 inhibitors. BTCP (37a, IC50: 42.6 μM, MTT assay) is not inferior to doxorubicin (IC50: 38.2 μM) against A549 cells, and BTPT (37b, IC50: 0.68 μM, MTT assay) with the thiophene moiety at the para position of the pyridine moiety holds enhanced activity against A549 cells (Murugavel et al., 2019; Murugavel et al., 2019).

An antiproliferative SAR study of 1,2,3-triazole–containing pyridine derivatives 38 against A549 cells demonstrates that the
methyl group on the 1,2,3-triazole motif and the fluoro on the phenyl ring are advantageous to the activity (Xiong et al., 2020). The morpholino group is essential for high activity, while replacement by pyrrolidiny1, thienyl, and alkyl groups leads to great loss of activity. In particular, compounds 38a-c (IC50: 3.22–6.43 μm, MTT assay) are more potent than golvatoinib (IC50: 8.14 μm), and the most active compound 38b could block cells in the G0/G1 phase. 1,2,3-Triazole–containing isoxazole–thiazole–pyridine hybrids 39 (IC50: 0.01–10.22 μm, MTT assay) has promising activity against A549 cells, and an SAR study implies that electron-withdrawing groups, especially the nitro group on the phenyl ring, could greatly increase the activity (Yakantham et al., 2019). The most active hybrid 39b (IC50: 0.01 μm) is 308-fold more potent than etoposide (IC50: 3.08 μm) against A549 cells, so it could serve as a lead compound for further development of novel anti–lung cancer candidates.

1,2,3-Triazole–containing imidazopyridines 42 (IC50: 0.51–47.92 μm, MTT assay) show considerable activity against A549 cells, and an SAR study illustrated that a substitution at the R2 position, regardless if the substituent is an electron-donating or electron-withdrawing group, could reduce the activity as compared with hydrogen (Sayeed et al., 2018). In particular, compounds 42a,b (IC50: 0.51 and 0.63 μm) are more potent than nocodazole (IC50: 1.47 μm) against A549 cells. Flow cytometry reveals that these compounds result in A549 cell cycle arrest at the G2/M phase, and further studies indicates that these compounds could inhibit tubulin and induce cell death by apoptosis.

**1,2,3-TRIAZOLE–CONTAINING PYRIMIDINE/QUINAZOLINONE/NUCLEOSIDE DERIVATIVES**

Pyrimidines, quinazolinones, and nucleosides could inhibit various MDR proteins, such as P-gp and MDR-associated protein-1, and several pyrimidine-/quinazolinone-/nucleoside-based agents, such as azacitidine and gemcitabine, demonstrate...
high efficacy for a broad spectrum of cancers (Robak, 2011; Patil, 2018; He et al., 2020). Therefore, 1,2,3-triazole–containing pyrimidine/quinazolinone/nucleoside derivatives may have the potency to overcome MDR, and they may represent promising leads for the development of novel anticancer agents.

1,2,3-Triazolo(4,5-d)pyrimidine 43 (Figure 8, IC50: 2.37 μm, MTT assay) is 3.3 folds more potent than 5-flourouracil (IC50: 7.86 μm) against NCI-H1650 cells, and mechanistic studies disclose that this compound can inhibit the migration of cancer cells and induce apoptosis (Geng et al., 2018). 1,2,3-Triazole–containing pyrimidine derivatives 44a,b (IC50: 0.29–0.91 μm, MTT assay) hold potential activity against A549 and the NSCLC cell line H2228 expressing EML4-ALK, and both of them display superior activity to crizotinib (IC50: > 1 μm) and ceritinib (IC50: > 1 μm) against A549 cells (Wang et al., 2018). Further study indicates that these compounds could induce cell apoptosis and inhibit cellular ALK and ROS1 activities. Accordingly, these compounds could act as promising ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants. 1,2,3-Triazole-pyrrolopyrimidine/imidazo(2,3-d)pyrimidine/thieno(3,2-d)pyrimidines also possess certain activity against lung cancer cell lines, and among them, compound 45 (IC50: 0.9 μm, MTT assay) is 5.2 times more potent than foretinib (IC50: 4.7 μm) against A549 cells (Lee et al., 2016; Bistrovic et al., 2018; Wang et al., 2018). A mechanistic investigation reveals that compound 45 could...
induce apoptosis in a concentration-dependent manner (Wang et al., 2018). The majority of 1,2,3-triazole-containing purine derivatives 46 (IC50: 0.03–45.2 μm, SRB assay) display inhibitory activity against A549 cells, and three compounds 46a-c (IC50: 0.03–0.14 μm) are 35–163.3 folds more potent than 5-fluorouracil (IC50: 4.9 μm), revealing the potential of these compounds as novel anti-lung cancer agents (Khazir et al., 2020).

1,2,3-Triazole–containing dihydropyrimidinone derivatives 47a (GI50: 14 and 18 μm, SRB assay) and its derivative 47b (GI50: 15 and 17 μm) show considerable activity against SW1573 and A549 lung cancer cell lines (Caeceiro et al., 2020), but incorporation of the second dihydropyrimidinone fragment does not positively affect the activity; as evidenced by that compound the second dihydropyrimidinone fragment does not positively affect the activity. The dihydropyrimidinone 47a-i (IC50: 1.18–2.81 μm, MTT assay) are more potent than pemetrexed (IC50: 3.29 μm) against A549 cells, and an SAR study illustrates that the chloro on the phenyl rings enhance the activity (Lu et al., 2019). Flow cytometric analysis shows that compound 49g could inhibit the proliferation of A549 cells by arresting the cell cycle in the G1/S phase and inducing cell apoptosis. The 1,2,3-triazole–containing 3H-pyra[2,3-d]pyrimidinone-6-carboxylate 50 (IC50: 0.69 μm, MTT assay) shows slightly lower potency than the reference doxorubicin (IC50: 0.14 μm) against A549 cells, demonstrating its potential as a lead compound for further development of new therapeutic drug candidates (Boda et al., 2018). 1,2,3-Triazole–containing pyrido[2,3-d]pyrimidinones 51 (GI50: 0.03–5.53 μm, SRB assay) are active against A549 cells, and the most active compound 51a (GI50: 0.03 μm) is more potent than the reference nocodazole (GI50: 0.08 μm) (Kumar et al., 2016). Similar activity of compounds 52a,b (IC50: 3.06 and 4.69 μm, MTT assay) to 5-fluorouracil (IC50: 2.80 μm) is also observed, but both the compounds 52a,b (IC50: 2.22 and 0.04 μm) display high cytotoxicity toward normal NIH 3T3 cells (Gregoric et al., 2017). Compound 53 (IC50: 1.34 μm, MTT assay) also exhibits considerable activity against A549 cells, but it is less potent than combetastatin-A4 (IC50: 0.11 μm) (Ruddarraju et al., 2017).

Most of 1,2,3-triazole–containing quinazoline derivatives 54 (Figure 9, IC50: 1.03–9.16 μm, MTT assay) possess potential activity against SK-Lu-1 NSCLC, and the activity is superior to that of erlotinib (IC50: 99.76 μm) (Le-Nhat-Thuy et al., 2018). An SAR study implies that the introduction of a nitro group into the ortho position of the phenyl ring at the N-1 position of the 1,2,3-triazole moiety could boost the activity to some extent. The representative compounds 54a,b (IC50: 1.03 and 1.81 μm) possess comparable activity to ellipticine (IC50: 1.38 μm), and molecular docking studies indicates that these compounds could exert antiproliferative activity through targeting EGFR.

Some 1,2,3-triazole–containing quinazolin-4(3H)-one derivatives also demonstrate considerable activity against lung cancer cell lines, and an antiproliferative SAR study of compounds 55 (IC50: 2.01–12.34 μm, MTT assay) against NCI-H23 lung cancer cells elucidates that introduction of substituents into the quinazolin-4(3H)-one motif, especially at the C-7 position, is unfavorable to the activity (Safavi et al., 2018; Vasu et al., 2018; Lan et al., 2020). No inferior activity is found for compounds 55a-c (IC50: 2.01–2.69 μm) compared with doxorubicin (IC50: 1.29 μm) and SAHA (IC50: 1.44 μm), and compounds 55a-c are around six folds more potent than 5-fluorouracil (IC50: 13.45 μm). The most active compound 55a could induce early apoptosis and arrest at the G2/M phase. Thus, it could serve as a new lead for the design and development of potent anticancer agents.
The majority of 1,2,3-triazole–tethered azidothymidine–quinazoline hybrids (IC\textsubscript{50} > 200 $\mu$m, MTT assay) are devoid of activity against SK-Lu-1 NSCLC, whereas the activity of hybrid 56 (IC\textsubscript{50} = 9.06 $\mu$m, MTT assay) is at the same level as that of ellipticine (IC\textsubscript{50} = 1.30 $\mu$m), and 3.4 times higher than that of erlotinib hydrochloride (IC\textsubscript{50} = 31.15 $\mu$m) (Giang et al., 2018). The 1,2,3-triazole–tethered nucleoside-theophylline hybrids 57a,b (IC\textsubscript{50} = 1.56 and 2.89 $\mu$m, MTT assay) also display certain activity against A549 cells, but the activity is considerably inferior to that of combretastatin-A4 (IC\textsubscript{50} = 0.11 $\mu$m) (Ruddarraju et al., 2016; Trznadel et al., 2019).

1,2,3-TRIAZOLE–CONTAINING STEROID DERIVATIVES

Steroids that are ubiquitous in natural resources are involved in several physiological functions and exhibit low cytotoxicity, high bioavailability, and excellent efficiency against diverse cancers, including lung cancers (Tantawy et al., 2017; Xiao et al., 2020). Thus, combination of 1,2,3-triazole with steroid is an attractive strategy to develop novel anticancer drug candidates.

1,2,3-Triazole–containing betulinic acid derivatives 58 (Figure 10, IC\textsubscript{50} = 3.7–9.0 $\mu$m, MTT assay) show promising cytotoxic potential against A549 cells, and the activity is higher than that of the parent betulinic acid (IC\textsubscript{50} = 23.0 $\mu$m) (Khan et al., 2016; Dangroo et al., 2017; Grishko et al., 2017). An SAR study suggested that hydrogen bond donors, such as hydroxyl and carboxylic acid, at the meta position of the phenyl ring on the N-1 position of the 1,2,3-triazole moiety are beneficial for their activity. Further studies demonstrated that compound 58a could arrest the G1 phase of the cell cycle and induce apoptosis, which confers its anti-invasive and anti-metastatic behavior toward cancer cells. An antiproliferative SAR study of 1,2,3-triazole–containing diosgenin derivatives 59 (IC\textsubscript{50} = 5.54–31.00 $\mu$m, MTT assay) against A549 cells indicates that introduction of electron-donating or electron-withdrawing groups into the phenyl ring is detrimental to the activity (Masood-Ur-Rahman et al., 2017). Among them, four compounds 59a-d (IC\textsubscript{50} = 5.54–7.23 $\mu$m) are comparable to BEZ-235 (IC\textsubscript{50} = 6.52 $\mu$m) but more potent than diosgenin (IC\textsubscript{50} = 13.3 $\mu$m). Most 1,2,3-triazole–containing dehydroepiandrosterone derivatives 60 (IC\textsubscript{50} = 7.6–75.2 $\mu$m, MTT assay) are active against A549 cells, and these compounds exert antiproliferative effects by arresting cells in the G2 phase of the cell cycle and inducing apoptosis (Huang et al., 2018).

1,2,3-Triazole–containing asiatic acid derivatives 61 (IC\textsubscript{50} = 2.67–39.87 $\mu$m, MTT assay) show promising activity against A549, NCI-H460, and NCI-H460/DOX lung cancer cell lines, and an SAR study reveals that the electron-withdrawing group at the ortho position of the phenyl ring is favorable to the activity (Huang et al., 2019). The representative compound 61a (IC\textsubscript{50} = 2.67–4.84 $\mu$m) is the most active against the three tested lung cancer cell lines, and the RI value is 1.08, suggesting its potential to fight against drug-resistant lung cancer. Moreover, compound 61a (IC\textsubscript{50} > 50 $\mu$m) is nontoxic toward normal HL-7702 cells, and the SI values are > 10.3. Mechanistic studies illustrate that compound 61a is a potential NF-κB inhibitor and could induce apoptosis and suppress cell migration. Accordingly, rational design of 1,2,3-triazole–containing asiatic acid derivatives may offer a new class of NF-κB inhibitors with the ability to suppress cancer cell migration and induce apoptosis.

Apart from the 1,2,3-triazole–containing steroid derivatives discussed above, some other derivatives also possess certain activity against lung cancer cell lines (Zhu et al., 2015; Zhang et al., 2018; Popov et al., 2020; Treyakova et al., 2020). 1,2,3-Triazole–containing celastrol derivatives 62a,b (IC\textsubscript{50} = 7.6–39.87 $\mu$m, MTT assay) also display certain activity against SK-Lu-1 NSCLC, whereas the activity of hybrid 56 (IC\textsubscript{50} = 9.06 $\mu$m, MTT assay) is at the same level as that of ellipticine (IC\textsubscript{50} = 1.30 $\mu$m), and 3.4 times higher than that of erlotinib hydrochloride (IC\textsubscript{50} = 31.15 $\mu$m) (Giang et al., 2018). The 1,2,3-triazole–tethered nucleoside-theophylline hybrids 57a,b (IC\textsubscript{50} = 1.56 and 2.89 $\mu$m, MTT assay) also display certain activity against A549 cells, but the activity is considerably inferior to that of combretastatin-A4 (IC\textsubscript{50} = 0.11 $\mu$m) (Ruddarraju et al., 2016; Trznadel et al., 2019).
0.97–54.94 μm, MTT assay) show broad-spectrum antiproliferative activity, and compound 62a (IC50: 3.53 μm) is comparable to celastrol (IC50: 3.02 μm) against A549 cells (Zhang et al., 2018). An SAR study demonstrates that the 1,2,3-triazole moiety is not essential for the activity and that the removal of this moiety exerts minimal influence on the activity.

MISCELLANEOUS 1,2,3-TRIAZOLE–CONTAINING COMPOUNDS

1,2,3-Triazole–tethered dihydroartemisinin–chalcone hybrid 63 (Figure 11, IC50: 7.16 μm, MTT assay) display comparable activity to doxorubicin (IC50: 6.36 μm), but it is more potent than dihydroartemisinin (IC50: 43.43 μm) against A549 cells, and this hybrid (IC50 > 100 μm) is nontoxic toward human erythrocyte and normal kidney cells (HEK-293) (Kapkoti et al., 2018). An SAR study implies that incorporation of the second dihydroartemisinin moiety could boost the activity to some extent. Mechanistic studies reveal that hybrid 63 significantly induces the ROS formation in A549 cells and causes cell cycle arrest at the G2/M phase as well as apoptosis in cancer cells.

1,2,3-Triazole–containing naphthoquinones 64 (IC50: 8.33–84.14 μm, MTT assay) show considerable activity against A549 cells, and an SAR study demonstrated that the alkyl or alkoxy group at the para position of the phenyl ring has advantages to the activity (Prasad et al., 2018). Among them, compound 64b (IC50: 9.19 μm) is slightly more active than tamoxifen (IC50: 10.87 μm), and it could arrest the cell cycle at the G0/G1 phase and induce apoptotic cell death. Accordingly, compound 64b could be taken as a lead molecule for further development of potent anti–lung cancer therapeutic agents. In LL2 (Lewis lung cancer, bearing a high expression level of IDO1) and Hepa1–6–xenografted mouse models, compound 65 (30 mg/kg, intraperitoneally) demonstrates moderate in vivo anticancer efficacy with TGI rates of 62.5% and 80%, and the potency is higher than that of epacadostat (TGI: 50.0%) (Pan et al., 2020). Moreover, in vivo experiments reveal no obvious body
weight change, implying its excellent safety profile. Therefore, compound 65 could serve as a preclinical candidate for further evaluations.

1,2,3-Triazole–containing hydroxamic acid 66 (IC50: 57.5 μm, MTT assay) not only displays comparable activity to 5-fluorouracil (IC50: 37.9 μm) against A549 cells but also exhibits synergistic effect with 5-fluorouracil (IC50: 16.6 μm) (Cao et al., 2019). Further studies showed that compound 66 (IC50: 32 nM) is a potential aminopeptidase N inhibitor, and it is nontoxic toward normal HUVECs (IC50: > 2000 μm). In addition, in the H22-xenografted mouse model, compound 66 alone or in combination with 5-fluorouracil could effectively inhibit tumor growth without causing loss of body weight. 1,2,3-Triazole–tethered dihydropyridin-2-one-hydroxamic acid hybrid 67 (IC50: 35 and 49 nM) is a potential HDAC1 and HDAC6 inhibitor, and it (IC50: 8.8 μm, MTT assay) is as potent as SAHA (IC50: 8.9 μm) against A549 cells (Li and Han, 2016). Moreover, hybrid 67 (IC50: > 50 μm) is nontoxic toward normal RWPE-1 and VERO cells, and SI > 5.6. Compound 68 reveals outstanding potency (IC50: 1.1–10.3 nM) against EGFR, HDAC1, and HDAC6 and promising activity (IC50: 0.71 and 7.85 μm, MTT assay) against A549 and NCI-H1975 lung cancer cell lines, and its antiproliferative activity is also superior to that of vorinostat (IC50: 2.67 and 23.76 μm) (Ding et al., 2017). Thus, this compound could act as a potential candidate for clinical applications. 1,2,3-Triazole–tethered clarithromycin-hydroxamic acid hybrid 69 (IC50: 23.9 and 2.85 nM) demonstrates excellent inhibitory activity against HDAC1 and HDAC6, and the activity of this hybrid (IC50: 0.99 and 0.69 μm, MTT assay) is around five-fold higher than that of SAHA (IC50: 5.00 and 3.27 μm) against A549 cells (Tapadar et al., 2015).

Some 1,2,3-triazole–containing sugar derivatives also possess certain antiproliferative activity against lung cancer cell lines (Petrova et al., 2015; Nagarsenkar et al., 2016; Li et al., 2018; Jakukowski et al., 2020; Tsai et al., 2020; Zi et al., 2020), and 1,2,3-triazole–tethered β-D-ribofuranose-pyridine hybrid 70 (IC50: 17.7 μm, MTT assay) is 3.4-fold more potent than cisplatin (IC50: 17.7 μm) against A549 cells (Jakukowski et al., 2020), whereas hybrids 71 (IC50: 0.18–54.89 μm, MTT assay) are more active than 5-fluorouracil (IC50: 69.07 μm) (Li et al., 2018). An SAR study suggests that the electron-donating group benefits the activity compared with the electron-withdrawing group on the phenyl ring, and replacement of the phenyl ring by the pyridinyl ring results in significant loss of activity. In particular, hybrids 71a,b (IC50: 0.18 and 0.28 μm) are highly potent against A549 cells, and mechanistic investigations...
demonstrate that these hybrids could inhibit the proliferation by inducing apoptosis and arresting the cell cycle at the G1 and S phases.

1,2,3-Triazole–containing colchicine derivative 72 (IC_{50}: 3.5 mM, MTT assay) shows remarkable cytotoxic efficacy against A549 cells, and the activity is 3.7-fold higher than that of paclitaxel (IC_{50}: 13.2 mM), revealing the potential of 1,2,3-triazole–containing colchicine derivatives as novel anti-lung cancer candidates (Thomopoulou et al., 2016).

1,2,3-Triazole–containing rapamycin derivatives (IC_{50}: 12.4–17.9 μM, MTT assay) show higher activity than the parent rapamycin (IC_{50}: 18.1 μM) against A549 cells, and compound 73 (Figure 12, IC_{50}: 12.8 μM) could induce apoptosis and cell cycle arrest in A549 cells (Huang et al., 2018). Moreover, compound 73 inhibits the phosphorylation of mTOR and its downstream key kinases 4EBP1 and p70S6K1 in A549 cells, revealing that this compound could also display effective inhibitory effect on the mTORC1 signaling pathway as rapamycin. Accordingly, compound 73 has the potential to be developed as a new mTOR inhibitor against lung cancers.

1,2,3-Triazole–containing bergenin derivatives 74 (IC_{50}: 1.86–23.05 μM, MTT assay) are endowed with considerable activity against A549 cells, and an SAR study demonstrates that the trifluoromethyl group on the phenyl ring is beneficial for the activity (Kumar et al., 2019). In particular, compound 74a (IC_{50}: 1.86 μM, MTT assay), which is comparable to doxorubicin (IC_{50}: 1.98 μM), demonstrates potent activity. Cell cycle analysis show that compound 74a could induce G2/M phase arrest and lead to the accumulation of cyclin B1 protein. Cell-based tubulin polymerization assays and docking studies implies that compound 74a disrupts tubulin assembly by occupying the colchicine binding pocket of tubulin.

1,2,3-Triazole–containing homoerythrina derivative 75 (IC_{50}: 1.89 μM, MTT assay) has excellent inhibitory activity to A549 cells, which is higher than those of pemetrexed (IC_{50}: 3.39 μM), rucaparib (IC_{50}: 4.91 μM), and harringtonine (IC_{50}: 10.55 μM) (Li et al., 2020). 1,2,3-Triazole–containing erythrina derivatives 76a,b (IC_{50}: 0.94 and 0.98 μM, MTT assay) show enhanced activity against A549 cells, and the activity is ~5 times superior to that of rucaparib (IC_{50}: 4.69 μM) (Li et al., 2020). Flow cytometry analysis shows that these hybrids not only significantly arrest the cell cycle in the S phase but also induce the apoptosis of the cells. Further studies suggest that these compounds could inhibit the expression of cyclin A, downregulate the expression of bcl-2/bax, activate caspase-3, and ultimately induce the apoptosis of A549 cells.

A significant part of 1,2,3-triazole–containing methoxygenipin derivatives 77 (IC_{50}: 4.53–47.18 μM, SRB assay) are active against A549 cells, whereas the parent genipin (IC_{50}: > 20.0 μM) is devoid of activity (Silalai et al., 2020). An SAR study implies that the introduction of dibenzyl ether substituted silyl and long-chain aliphatic groups into the C-10 position of the genipin moiety could increase the activity. Compounds 77a,b (IC_{50}: 4.81 and 4.53 μM) are the most active against A549 cells. Thus, both of them merit further investigations. 1,2,3-Triazole–containing bavachinin derivative 78 (IC_{50}: 7.72 μM, SRB assay) is more potent than bavachinin (IC_{50}: 30.5 μM) against A549 cells, and a mechanistic study reveals that this compound could induce apoptotic cell death through loss of MMP and PARP cleavage (Gupta et al., 2018). Compound 78 could also inhibit the colony formation, cell migration, and induce the morphological changes concentration-dependently.

1,2,3-Triazole–containing melampomagnolide B derivatives 79 (IC_{50}: 1.17–34.13 μM, MTT assay) show considerable activity against A549 cells, and most of them are more potent than the parent melampomagnolide B (IC_{50}: 9.94 μM) (Ding et al., 2018). The representative compound 79d (IC_{50}: 1.35 μM) shows significant efficacy by inducing apoptosis, inhibiting the proliferation and migration of cancer cells. Thus, this compound might be considered as a promising anticancer drug candidate for further evaluation. 1,2,3-Triazole–tethered Jiyuan Oridonin A–thiazolin-dione hybrids 80a,b (IC_{50}: 3.5 and 4.8 μM, MTT assay) demonstrates higher activity than Jiyuan Oridonin A (IC_{50}: 16.4 μM) against A549 cells, and further mechanistic studies reveals that hybrid 80a has inhibition on the proliferation of cancer cells by inducing apoptosis and arresting the cell cycle at the G1 phase (Ke et al., 2018).

1,2,3-Triazole–containing L-ascorbic acid derivative 81 (IC_{50}: 0.75–9.42 μM, MTT assay) possesses excellent antiproliferative activity against A549 cells, whereas the parent L-ascorbic acid (IC_{50}: > 100 μM) is inactive, suggesting that 1,2,3-triazole–containing L-ascorbic acid derivatives may be promising for the discovery of novel anti-lung cancer agents (Harej et al., 2019; Macan et al., 2019).

1,2,3-Triazole–containing phosphonate derivatives 82a,b (IC_{50}: 2.0 and 3.0 μM, MTT assay) show potential activity against A549 cells, and the activity is superior to that of doxorubicin (IC_{50}: 4.4 μM), revealing that these compounds warrant further investigations (Makarov et al., 2015). Additionally, the activity of 1,2,3-triazole–containing dibenzo[b,e][1,4]diazepin-11-one hybrid 83 (IC_{50}: 0.71 μM, MTT assay) against A549 cells is much higher than that of 5-fluorouracil (IC_{50}: 3.47 μM), and this hybrid could induce the G2/M phase of cell cycle arrest and apoptosis, indicating that hybrid 83 could be used for further studies as anti-lung cancer candidates (Praveen Kumar et al., 2016).

Some other compounds which are combined by 1,2,3-triazole and benzodiazepine/benzoxepine/dithiocarbamate/deoxysalninomycin/myrhnanone B /phendrin/parenovan/pyran0(2,3-c) phenzine/paeonol/naphthalimide/sesquiterpene/sulfonate ester/sapinofuranone/triterpene/thiourea/benzothiazinone/benzoxazinone/furan/nimesulide (Kuntala et al., 2015; Poormina et al., 2015; Sudharpriya et al., 2015; Chandrashekhar et al., 2016; Reddy et al., 2016; Shaikh et al., 2016; Abdallah et al., 2017; Battula et al., 2017; Kumar et al., 2017; Lu et al., 2017; Maddrey et al., 2017; Mo et al., 2017; Nguyen et al., 2017; Li et al., 2018; Narsimha et al., 2018; Ou et al., 2019; Yang et al., 2019; Jiang et al., 2020; Kanabar et al., 2020; Madasu et al., 2020; Qi et al., 2020; Zhang et al., 2020) also possess certain activity against lung cancer cell lines, but their activities are generally far inferior to those of the references. Hence, these derivatives still need further structural modifications.
CONCLUSIONS

Lung cancer, as a cancer with the highest morbidity, is the leading cause of cancer-related deaths and has already posed heavy burden on the world health system, which makes an urgent need to develop novel anti-lung cancer agents. 1,2,3-Triazole could readily interact with diverse enzymes and receptors in organisms through weak interaction and has been considered as a privileged structure in medicinal chemistry. 1,2,3-Triazole–containing agent CAI synergizes with sorafenib to combat NSCLC through the inhibition of NANOG and aggravation of apoptosis, indicating that 1,2,3-triazole–containing derivatives are useful scaffolds to develop novel anti-lung cancer agents.

The azide-alkyne cycloaddition reaction is the major strategy to synthesize 1,2,3-triazoles. The thermal Huisgen 1,3-dipolar cycloaddition usually results in poor regioselectivity, but the Huisgen cycloaddition catalyzed by metal catalyst could give excellent regioselectivity. For example, the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) usually affords 1,4-disubstituted 1,2,3-triazoles, whereas ruthenium(II)-catalyzed azide-alkyne cycloaddition often provides 1,5-disubstituted triazoles. However, azides are energy-rich and potentially explosive substances, so synthesis of azides should be careful. Even though various 1,2,3-triazoles showed poor solubility, combination of the 1,2,3-triazole moiety with the other pharmacophores demonstrated good solubility, and may solve the issue of solubility.

This review summarizes the current developments, mechanisms of action and SAR of a series of 1,2,3-triazole–containing derivatives (chromene/coumarin, chalcone, 1,2,3-triazole-indole, podophyllotoxin/epipodophyllotoxin, quinoline/quinolone, pyridine, pyrimidine/quinazolinone/nucleoside, and steroid derivatives), and some of them suggest great in vitro and in vivo efficacy. Overall, rational design of 1,2,3-triazole–containing derivatives may provide novel anticancer agents with excellent potency against various lung cancers, including drug-resistant forms.

AUTHOR CONTRIBUTIONS

TL, FG, and GH wrote section 1–6. WL and XS wrote section 7–11. FG and GH collected the whole manuscript. TL and XS corrected the manuscript. All authors read and approved the final manuscript.

FUNDING

This research was funded by grants from the National Natural Science Foundation of China (81371601) and the Natural Science Foundation of Shandong Province (ZR2019MH019, ZR2019BA015), and also got the support from Science & Technology Department of Sichuan Province (2019YJ0674).

ACKNOWLEDGMENTS

This work gained great support by core facilities sharing platform of Shandong University.

REFERENCES

Abdallah, W., Znati, M., Regazzetti, A., Dargère, D., Lagrévoire, O., Ben Jannet, H., et al. (2017). Synthesis of S-Mono- and S,O-bis-1,2,3-triazole Linked 1,5-benzodiazepine Conjugates and Their Cytotoxic, Anti-tyrosinase, and Anti-cholinesterase Activities. *Phosphorus, Sulfur Silicon Relat. Elem.* 192 (7), 835–844. doi:10.1080/10426507.2017.1287704

Al-Warthi, T., Sabt, A., Elkaeed, E. B., and Eldehna, W. M. (2020). Recent Advancements of Coumarin-Based Anticancer Agents: An Up-To-Date Review. *Bioorg. Chem.* 103, e104163. doi:10.1016/j.bioorg.2020.104163

Bade, B. C., and Dela Cruz, C. S. (2020). Lung Cancer 2020. *Clin. Chest Med.* 41 (1), 1–24. doi:10.1016/j.ccvm.2019.10.001

Battula, K. S., Narsimha, S., Thatapamula, R. K., Reddy, Y. N., and Nagavelli, V. R. (2017). Synthesis and Biological Evaluation of N-(3-methoxyphenyl)-4-((aryl-1H -1,2,3-Triazol-4-Yl)methyl)thiomorpholine-2-Carboxamide 1,1-Dioxide Hybrids as Antiproliferative Agents. *ChemistrySelect* 2, 9595–9598. doi:10.1002/slct.201701902

Bistrovic, A., Grbic, P., Harej, A., Sedic, M., Kraljevic-Pavelic, S., Kostrun, S., et al. (2018). Small Molecule Purine and Pseudopurine Derivatives: Synthesis, Cytostatic Evaluations and Investigation of Growth Inhibitory Effect in NSCLC Cells. *Eur. J. Med. Chem.* 161, 91–101. doi:10.1016/j.ejmech.2018.05.013

Chandrashekhar, M., Nayak, V. L., Ramakrishna, S., and Mallavadhani, U. V. (2016). Novel Triazole Hybrids of Myrrhanone C, a Natural Polypodane Triterpene: Synthesis, Cytotoxic Activity and Cell Based Studies. *Eur. J. Med. Chem.* 114, 293–307. doi:10.1016/j.ejmech.2016.03.013

Chen, C., Ju, R., Shi, J., Chen, W., Sun, F., Zhu, L., et al. (2017). Synthesis and Biological Evaluation of (N-(3-methoxyphenyl)-4-((aryl-1H -1,2,3-Triazol-4-Yl)methyl)thiomorpholine-2-Carboxamide 1,1-Dioxide Hybrids as Antiproliferative Agents. *ChemistrySelect* 2, 9595–9598. doi:10.1002/slct.201701902

Boda, S. K., Pishka, V., Lakshmi, A., Chinde, S., and Grover, P. (2018). 1,2,3-Triazole Tagged 3H-Pyran-2,3-Dipyrimidine-6-Carboxylate Derivatives: Synthesis, In Vitro Anticancer Activity, Molecular Docking and DNA Interaction Studies. *Chem. Biol. Divers.* 15, e1800010. doi:10.1002/cbdv.201800101

Bonandi, E., Christodoulou, M. S., Fumagalli, G., Perdicchia, D., Rastelli, G., and Passarella, D. (2017). The 1,2,3-triazole Ring as a Bioscaffold in Medicinal Chem. Drug Discov. Today 22 (10), 1572–1581. doi:10.1016/j.drudis.2017.05.014

Boratynski, P. J., Galezowska, J., Turkowiak, K., Anisiewicz, A., Kowalczyk, R., and Wietrzyk, J. (2018). Triazole Biheterocycles from *Cinchona* Alkaloids: Coordination and Antiproliferative Properties. *ChemistrySelect* 3, 9563–9573. doi:10.1002/slct.201801810

Bozorov, K., Zhao, J., and Aisa, H. A. (2019). 1,2,3-Triazole-containing Hybrids as Leads in Medicinal Chemistry: A Recent Overview. *Bioorg. Med. Chem.* 27 (16), 3511–3531. doi:10.1016/j.bmc.2019.07.005

Caceireiro, E. P., Sena, A. M., Puerta, A., Padron, J. M., and Burke, A. J. (2020). Synthesis of Novel 1,2,3-Triazole-Dihydropyrimidinone Hybrids Using Multicomponent 1,3-dipolar Cycloaddition (Click)-Cigelline Reactions: Anticancer Activity. *Synlett* 31, 615–621. doi:10.1055/s-0039-1690781

Cao, J., Zang, J., Kong, X., Zhao, C., Chen, T., Ran, Y., et al. (2019). Leucine Ureido Derivatives as Aminopeptidase N Inhibitors Using Click Chemistry. Part II. *Bioorg. Med. Chem.* 27, 978–990. doi:10.1016/j.bmc.2019.01.041

Chandrasekhar, M., Nayak, V. L., Ramakrishna, S., and Mallavadhani, U. V. (2016). Novel Triazole Hybrids of Myrrhanone C, a Natural Polypodane Triterpene: Synthesis, Cytotoxic Activity and Cell Based Studies. *Eur. J. Med. Chem.* 114, 293–307. doi:10.1016/j.ejmech.2016.03.013

Chen, C., Ju, R., Shi, J., Chen, W., Sun, F., Zhu, L., et al. (2017). Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis. *J. Pharmocol. Exp. Ther.* 362 (2), 219–229. doi:10.1124/jpet.117.240986

Chen, R., Zhang, H., Ma, T., Xue, H., Miao, Z., Chen, L., et al. (2019). Moxi Anticancer Activity. *J. Heterocyclic Chem.* 56, 2691–2694. doi:10.1002/jhet.3670

This research was funded by grants from the National Natural Science Foundation of China (81371601) and the Natural Science Foundation of Shandong Province (ZR2019MH019, ZR2019BA015), and also got the support from Science & Technology Department of Sichuan Province (2019YJ0674).
Kamal, A., Subba Rao, A. V., Vishnuvardhan, M. V. P. S., Srinivasa Reddy, T., Swapna, K., Bagul, C., et al. (2015). Synthesis of 2-Anilinopyridyl-1-Triazole Conjugates as Antimitotic Agents. Org. Biomol. Chem. 13, 4879–4895. doi:10.1039/C3OB30022J

Kanabar, D., Farrales, P., Kabir, A., Juang, D., Gnanmony, M., Almasri, J., et al. (2020). Optimizing the Aryl-Triazole of Cjoc42 for Enhanced Gankyrin Binding and Anti-cancer Activity. Bioorg. Med. Chem. Lett. 30, e127372. doi:10.1016/j.bmcl.2020.127372

Kandi, S. K., Manohar, S., Vélez Gerena, C. E., Zayas, B., Malhotra, S. V., and Lan, T. T., Anh, D. T., Hai, P.-T., Dung, D. T. M., Huong, L. T. T., Park, E. J., et al. (2018). Recent Advancements in 1, 4-disubstituted 1,2,3-Triazole- Containing Compounds as Antimitotic Agents. Bioorg. Med. Chem. Lett. 28, 3741–3747. doi:10.1016/j.bmcl.2018.10.016

Lee, S.-M., Yoon, K. B., Lee, H. J., Kim, J., Chung, Y. K., Cho, W.-J., et al. (2016). The Discovery of 2.5-isomers of Triazole-Pyrrolopyrimidine as Selective Janus Kinase 2 (JAK2) Inhibitors versus JAK1 and JAK3. Bioorg. Med. Chem. 24, 5036–5046. doi:10.1016/j.bmcl.2016.08.008

Li, H.-n., Wang, H., Wang, Z.-p., Yan, H.-n., Zhang, M., Liu, Y., et al. (2018). Synthesis, Antitumor Activity Evaluation and Mechanistic Study of Novel Hederacolchiside A1 Derivatives Bearing an Aryl Triazole Moiety. Bioorg. Med. Chem. 26, 4025–4033. doi:10.1016/j.bmcl.2018.06.026

Li, H.-T., and Zhu, X. (2021). Quinoline-based Compounds with Potential Activity against Drugresistant Cancers. Cmarc 21 (5), 426–437. doi:10.2174/15680266206662018113957

Li, J., Q., and Han, X. (2016). Synthesis and Anti-tumor Activity of Novel Histone Deacetylase Inhibitors Based on Dihydropyridin-2-One Scaffold. Yao Xue Xue Bao 51, 1734–1744. doi:10.16438/4870.2016.0503

Li, S., Li, X. Y., Zhang, T. J., Kamara, M. O., Liang, J. W., Zhu, J., et al. (2020). Design, Synthesis and Biological Evaluation of Homoeotrichylna Alkaloid Derivatives Bearing a Triazole Moiety as PARP-1 Inhibitors and as Potential Antitumor Drugs. Bioorg. Chem. 94, e103385. doi:10.1016/j.bioorg.2019.103385

Li, S., Li, X. Y., Zhang, T. J., Zhu, J., Xue, W. H., Qian, X. H., et al. (2020). Design, Synthesis and Biological Evaluation of etyrhina Derivatives Bearing a 1,2,3- triazole Moiety as PARP-1 Inhibitors. Bioorg. Chem. 96, e103755. doi:10.1016/j.bioorg.2020.103755

Li, X., Wu, Y., Wang, Y., You, Q., and Zhang, X. (2017). 'Click Chemistry' Synthesis of Novel Natural Product-like Caged Xanthones Bearing a 1,2,3-triazole Moiety with Improved Druglike Properties as Orally Active Antitumor Agents. Molecules 22, e1834. doi:10.3390/molecules22111834

Li, Y., Shi, Q., Shao, J., Yuan, Y., Yang, Z., Chen, S., et al. (2018). Synthesis and Biological Evaluation of 20-Epi-Amino-20-Deoxysalinomycin Derivatives. Eur. J. Med. Chem. 148, 279–290. doi:10.1016/j.ejmech.2018.02.004

Liu, C.-F., Shen, Q.-K., Li, J.-J., Tian, Y.-S., and Quan, Z. (2017). Synthesis and Biological Evaluation of Novel 7-Hydroxy-4-Phenylchromene-2-One-Linked to Triazole Moleitues as Potent Cytotoxic Agents. J. Enzyme Inhib. Med. Chem. 32 (1), 1111–1119. doi:10.1080/14756366.2017.1344982

Liu, M., Hou, Y., Yin, W., Zhou, S., Qian, P., Guo, Z., et al. (2016). Discovery of a Novel 6,7-Disubstituted-4-(2-Fluorophenoxy)quinolines Bearing 1,2,3-Triazole-4- Carboxamide Moleiy as Potent C-Met Kinase Inhibitors. Eur. J. Med. Chem. 119, 96–108. doi:10.1016/j.ejmech.2016.04.035

Lu, G.-q., Li, X.-y., Mohamed O, K., Wang, D., and Meng, F.-h. (2019). Design, Synthesis and Biological Evaluation of Novel Uracil Derivatives Bearing 1,2,3-triazole Moleiy as Thymidylate Synthase (TS) Inhibitors and as Potential Antitumor Drugs. Eur. J. Med. Chem. 171, 281–296. doi:10.1016/j.ejmech.2019.03.047

Lu, Y., Wang, L., Wang, X. T., Liao, J., Wang, Z., et al. (2017). Design, Combinatorial Synthesis and Biological Evaluations of Novel 3-Amino-1-{(1-Aryl-1 H -1,2,3-Triazol-5-Yl) methyl}-2 Oxospiro[benzo [ a ] Pyran-2,3- C ] phene-1,3'-Indoline]-2-Carbonitrile Antitumor Hybrid Molecules. Eur. J. Med. Chem. 135, 125–141. doi:10.1016/j.ejmech.2017.04.040

Luan, T., Quan, Z., Fang, Y., and Yang, H. (2020). Design, Synthesis and Antiproliferative Activity of Chrysiv Derivatives Bearing Triazole Moleiyes. Chin. J. Org. Chem. 40, 440–446. doi:10.6023/cjoc201907012

Macan, A. M., Harej, A., Cazin, I., Klobucar, M., Stepanic, V., Pavlic, K., et al. (2019). Antitumor and Antiviral Activities of 4-substituted 1,2,3-Triazolyl-2,3- Dibenzy1-4-Aminosaccharide Acid Derivatives. Eur. J. Med. Chem. 184, e111739. doi:10.1016/j.ejmech.2019.111739

Madasu, C., Karri, S., Sagararaju, R., Sistla, R., and Uppluri, M. V. (2020). Synthesis and Biological Evaluation of Some Novel 1,2,3-triazole Hybrids of Myrrnanhe B Isolated from Commiphora Mollu Gam Resin: Identification of Potent Antiproliferative Leads Active against Prostate Cancer Cells (PC-3). Eur. J. Med. Chem. 188, e111974. doi:10.1016/j.ejmech.2019.111974

Majem, B., Nadal, E., and Muñoz-Pinedo, C. (2020). Exploiting Metabolic Vulnerabilities of Non Small Cell Lung Carcinoma. Semin. Cell Develop. Biol. 98, 54–62. doi:10.1016/j.semcdb.2019.06.004
Wang, L., Liu, X., Duan, Y., Li, X., Zhao, B., Wang, C., et al. (2018). Discovery of Novel Pyrrolidinylpyrimidine/pyrazolopyrimidine Derivatives Bearing 1,2,3-triazole Moiety as C-Met Kinase Inhibitors. Chem. Biol. Drug Des. 92, 1301–1314. doi:10.1111/cbdd.13192

Wang, L., Xu, S., Liu, X., Chen, X., Xiong, H., Hou, S., et al. (2018). Discovery of Thiopurinyl-Triazole Conjugates as C-Met Targeting and Apoptosis Inducing Agents. Bioorg. Chem. 77, 370–380. doi:10.1016/j.bioorg.2018.01.037

Wang, Y., Chen, S., Hu, G., Wang, J., Gou, W., Zuo, D., et al. (2018). Discovery of Novel 2,4-diarylaminopyrimidine Analogues as ALK and ROS1 Dual Inhibitors to Overcome Crizotinib-Resistant Mutants Including G1202R. Eur. J. Med. Chem. 143, 123–136. doi:10.1016/j.ejmech.2017.11.008

Willis, C., Fiander, M., Tran, D., Korytowsky, B., Thomas, J.-M., Calderon, F., et al. (2019). Tumor Mutational burden in Lung Cancer: A Systematic Literature Review. Oncotarget 10 (61), 6064–6062. doi:10.18632/oncotarget.27287

Wu, J., Dai, J., Zhang, Y., Wang, J., Huang, L., Ding, H., et al. (2019). Synthesis of Novel Xanthone Analogues and Their Growth Inhibitory Activity against Human Lung Cancer A549 Cells. Ddtt 13, 4239–4246. doi:10.2147/ddtt.s217827

Xiao, J., Gao, M., Sun, Z., Diao, Q., Wang, P., and Gao, F. (2020). Nature-derived Anticancer Steroids outside Cardiac Glycosides. Filoteraapia 147, e104757. doi:10.1016/j.fiote.2020.104757

Xiong, H., Cheng, J., Zhang, J., Zhang, Q., Xiao, Z., Zhang, H., et al. (2020). Design, Synthesis, and Biological Evaluation of Pyridimide Derivatives Containing a 1,2,3-triazole Fragment as Type II C-Met Inhibitors. Molecules 25 (10), e3390. doi:10.3390/molecules25100010

Xu, D., and Xu, Z. (2020). Indole Alkaloids with Potential Anticancer Activity. Cmcc 20 (21), 1938–1949. doi:10.15486/cmcc.2019.6620622150325

Xu, Z. (2020). 1,2,3-Triazole-containing Hybrids with Potential Antibacterial Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). Eur. J. Med. Chem. 206, e122866. doi:10.1016/j.ejmech.2020.122866

Wang, R., Yin, X., Zhang, Y., Zhang, T., and Shi, W. (2018). Design, Synthesis, and In Vitro Anti-tumor Activities of 1,2,3-triazoletetraethylhylene Glycol Tethered Heteronuclear Bis-Schiff Base Derivatives of Isatin. J. Heterocyclic Chem. 55, 3001–3005. doi:10.1002/jhet.3341

Xu, Z., Zhao, S. J., and Liu, Y. (2019). 1,2,3-Triazole-containing Hybrids as Potential Anticancer Agents: Current Developments, Action Mechanisms and Structure-Activity Relationships. Eur. J. Med. Chem. 183, e11700. doi:10.1016/j.ejmech.2019.111700

Xu, Z., Zhao, S. J., Lv, Z. S., Gao, F., Wang, Y. L., Zhang, F., et al. (2019). Design, Synthesis, and Evaluation of Tetraethylhylene Glycol-Tethered Isatin-1,2,3-Triazol-Coumarin Hybrids as Novel Anticancer Agents. J. Heterocyclic Chem. 56, 1127–1132. doi:10.1002/jhet.3475

Yadav, P., Lal, K., Kumar, A., Guru, S. K., Jaglan, S., and Bhushan, S. (2017). Green Synthesis and Anticancer Potential of Chalcone Linked-1,2,3-Triazole Derivatives. J. Med. Chem. 60, 5407–5423. doi:10.1021/acs.jmedchem.7b00016

Zeng, B. (2019). Comprehensive Review on the Anti-bacterial Activity of 1,2,3-triazole Hybrids. Eur. J. Med. Chem. 168, 357–372. doi:10.1016/j.ejmech.2019.02.055

Zhang, H.-J., Zhang, G.-R., Piao, H.-R., and Quan, Z.-S. (2018). Synthesis and Characterisation of Celastrol Derivatives as Potential Anticancer Agents. J. Enzyme Inhib. Med. Chem. 33 (1), 190–198. doi:10.1080/14756636.2017.1404590

Zhang, S., Xu, Z., Gao, C., Ren, Q.-C., Zhang, L., Lv, Z.-S., et al. (2017). Triazole Derivatives and Their Anti-tubercular Activity. Eur. J. Med. Chem. 138, 501–513. doi:10.1016/j.ejmech.2017.06.051

Zhang, T., Li, Y., Zhang, H., Wang, X., Liu, X., and Li, L. (2020). The Role of RASSF1 Methylation in Lung Carcinoma. Adv. Exp. Med. Biol. 1255, 99–108. doi:10.1007/978-981-15-4494-1_8

Zhang, Y., Meng, X., Tang, H., Cheng, M., Yang, F., and Xu, W. (2020). Design, Synthesis, and Biological Evaluation of Novel Substituted Thiourea Derivatives as Potential Anticancer Agents for NSCLC by Blocking K-Ras Protein-Effectors Interactions. J. Enzyme Inhib. Med. Chem. 35 (1), 344–353. doi:10.1080/14756636.2019.1702653

Zhao, L., Mao, L., Hong, G., Yang, X., and Liu, T. (2015). Design, Synthesis and Anticancer Activity of Matrine-1H-1,2,3-Triazole-Chalcone Conjugates. Bioorg. Med. Chem. Lett. 25, 2540–2544. doi:10.1016/j.bmcl.2015.04.051

Zhu, R. X., Zhao, L., Zhang, Y. K., Luo, P., Liu, S. H., and Wang, J. G. (2015). Sequential Treatment with Ursolic Acid Chlorophenyl Triazole Followed by 5-fluorouracil Shows Synergistic Activity in Small Cell Lung Cancer Cells. Bangladesh J. Pharmacol. 10, 197–204. doi:10.3329/bjp.v1i10.21641

Zi, C.-T., Li, G.-T., Li, Y., Zhou, J., Ding, Z.-T., Jiang, Z.-H., et al. (2015). Synthesis and Anticancer Activity of 4β-Triazole-Podophyllotoxin Glycosides. Nat. Prod. Bioprospect. 5, 83–90. doi:10.1016/j.npbi.2015.05.007-3

Zi, C.-T., Liu, Z.-H., Li, G.-T., Li, Y., Zhou, J., Ding, Z.-T., et al. (2015). Design, Synthesis, and Cytotoxicity of Perbutyrylated Glycosides of 4β-Triazolopodophyllotoxin Derivatives. Molecules 20, 3255–3280. doi:10.3390/molecules20123255

Zi, C.-T., Yang, L., Gao, W., Li, Y., Zhou, J., Ding, Z.-T., et al. (2017). Click Glycosylation for the Synthesis of 1,2,3-Triazole-Linked Pircropodophyllotoxin Glycoconjugates and Their Anticancer Activity. ChemistrySelect 2, 5038–5044. doi:10.1002/slct.201700347

Zi, C.-T., Yang, L., Xu, F.-Q., Dong, F.-W., Yang, D., Li, Y., et al. (2018). Synthesis and Anticancer Activity of Dimeric Podophyllotoxin Derivatives. Ddtt 12, 3393–3406. doi:10.2147/ddtt.s167382

Zi, C.-T., Sun, P. Y., Zhang, N., Tang, H., Yang, H. N., Wang, Q., et al. (2020). Synthesis of (-)-Epigallocatechin-3-Gallate Derivative Containing a Triazole Ring and Combined with Cisplatin/paclitaxel Inhibits NSCLC Cancer Cells by Decreasing Phosphorylation of the EGFR. J. Chem. Res. 44, 44–49. doi:10.1177/147579892091390

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liang, Sun, Li, Hou and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.